Cytiva published an insight by Martin Ball exploring the shift from reacting to failures to predicting them using connected equipment, data, and AI.
Published
Signal category
Research & Knowledge
Quote
“Martin Ball explores this shift in our latest Cytiva insight”
— Nicolas Pivet|Cytiva team
Company
Cytiva
We envision a world in which access to life-changing therapies transforms human health.
- Industry
- Biotechnology Research
- Location
- Global, OO
- Company size
- 9,958 employees
Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader dedicated to helping customers discover and commercialize the next generation of therapeutics. We bring dedicated technical expertise and a broad portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients. We're the provider of leading life science brands such as ÄKTA, Amersham, HyClone, MabSelect and Whatman. We are part of Danaher, a global science and technology leader. Along with other Danaher businesses, we accelerate the impact of tomorrow’s science and technology innovation to improve human health. Visit https://www.cytiva.com/privacy to review our privacy policy.